Revvity

RVTY

Market cap $11.6B

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.

Revvity, Inc. ( RVTY ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Good morning, everybody, and thank you all for joining us for 8 a.m. session with Revvity.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative. The Somatic Reference Samples (SRS) Initiative is a public-private partnership convened and led by MDIC to guide the development of reference samples that can b.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals' solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce.

Revvity, Inc. (NYSE:RVTY) announced mixed third-quarter 2025 financial results on Monday.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu.

Revvity, Inc. operates across two main segments in Life Sciences tools and Diagnostics. Its cloud informatics Signals continue experiencing double-digit growth, while diagnostics in China suffer from macro headwinds. RVTY's latest Q3 2025 revenue figures were up 2% overall. For the most part, US and ex-China growth offsets China's decline.

Revvity, Inc. (NYSE:RVTY ) Q3 2025 Earnings Call October 27, 2025 8:00 AM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Prahlad Singh - CEO, President & Director Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Ryskin - BofA Securities, Research Division Daniel Leonard - UBS Investment Bank, Research Division Tycho Peterson - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Q3 2025 Revvity Earnings Conference Call.

Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.